Cangrelor is the only currently available intravenous platelet P2Y12 receptor inhibitor, and its quick onset and offset make it an appealing option for antiplatelet therapy[1]. In vitro, the experiment focused on αIIbβ3 complex (platelet receptor for fibrinogen), and cangrelor (140μM, 15 min) suppressed the expression of this surface membrane activation marker in platelets[2]. Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[3].
搜索
